home / stock / agnpf / agnpf news

AGNPF News and Press, Algernon Pharmaceuticals Inc - Class A From 11/16/22

Stock Information
Company Name: Algernon Pharmaceuticals Inc - Class A
Stock Symbol: AGNPF
Market: OTC
Website: algernonpharmaceuticals.com
Menu
AGNPF AGNPF Quote AGNPF Short AGNPF News AGNPF Articles AGNPF Message Board
Get AGNPF Alerts

News, Short Squeeze, Breakout and More Instantly...
AGNPF - Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that ...
AGNPF - Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video

Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF)  – The company is focused on the disease area of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease. Algernon was recently...

AGNPF - Yale University To Study DMT For Depression

Canadian clinical stage drug development company, Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF), has entered an investigator-initiated clinical trial agreement with Yale University for the investigation of multiple intravenous doses of DMT for the treatment of depr...

AGNPF - Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

VANCOUVER, British Columbia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has ente...
AGNPF - Algernon Pharmaceuticals Announces Dr. Rick Strassman author of "DMT: The Spirit Molecule" to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

VANCOUVER, British Columbia, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that D...

AGNPF - Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program

VANCOUVER, British Columbia, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it ha...

AGNPF - Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has dec...
AGNPF - Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

VANCOUVER, British Columbia, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has rec...

AGNPF - Microdose Announces Algernon Pharmaceuticals as Wonderland's Headline Sponsor

Miami, Florida--(Newsfile Corp. - September 8, 2022) - Microdose Psychedelic Insights , the leading guide to the business of psychedelics, is thrilled to announce Algernon Pharmaceuticals  (CSE: AGN) (FSE: AGW0) (OTCQB: AGNPF) ("Algernon") as the official Headline Sponsor for Wonderland...

AGNPF - Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami

VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that ...
Previous 10 Next 10